Vestibular schwannomas (VS) are benign neoplasms of the VIII cranial nerve; they account for 6-8% of all intracranial tumors and about 80% of tumors of the cerebellopontine angle. Cystic forms of VS may be particularly dangerous, as they demonstrate faster growth and worse postoperative outcomes....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable clinical change at this time; this is early-stage protein discovery research that does not yet inform diagnosis or treatment decisions.
Identifying the molecular drivers of vascular permeability in vestibular schwannoma may open new therapeutic targets and improve understanding of tumor-related hearing decline.
- 01Proteomic profiling was used to identify proteins associated with increased vascular permeability in vestibular schwannoma patients.
- 02Vascular permeability changes are thought to contribute to tumor growth and associated symptoms such as hearing loss.
- 03Findings published in Journal of Proteomics (2026); PMID 42901474.
- 04Study is translational/basic science; clinical translation will require further validation.
- 05May inform future targeted therapies or biomarker development for vestibular schwannoma.
Proteomic analysis can identify specific proteins involved in increased vascular permeability in vestibular schwannoma patients.
studypartially supported- PMID
- 42901474
- DOI
- 10.1016/j.jprot.2026.105751.
- Journal
- Journal of Proteomics
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients with vestibular schwannoma
- Intervention
- Proteomic analysis of tissue/fluid samples from vestibular schwannoma patients
Primary outcomes
Identification of proteins associated with increased vascular permeability in vestibular schwannoma